12 Citations (Scopus)

Abstract

Importance of the field: Follicular lymphoma (FL) is a subgroup of B-cell Non-Hodgkin's lymphomas (NHL) that account for 15 30% of all lymphomas. I-131 tositumomab is a radiommunoconjugate of 131I and the anti-CD20 monoclonal antibody tositumomab. It is one of two available radioimmunoconjugates for the treatment of recurrent, refractory, or transformed FL. Areas covered in this review: This review describes the clinical pharmacology of I-131 tositumomab, dosing and administration guidelines, and the key clinical trials providing evidence of its efficacy and safety in patients with FL, transformed, or other aggressive B-NHL, in combination with chemotherapy, or its incorporation in transplant conditioning regimens. This review also covers safety and regulatory concerns regarding the use of I-131 tositumomab. What the reader will gain: This review critically appraises the clinical trials behind approval of I-131 tositumomab as a second-line agent for FL and also outlines the data supporting its use in the upfront setting. Take home message: I-131 tositumomab is a safe and effective option for patients with recurrent, refractory, or transformed FL and carries promise in the upfront treatment of FL, aggressive B-NHL, and as a transplant conditioning regimen.

Original languageEnglish (US)
Pages (from-to)1271-1278
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume10
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Follicular Lymphoma
Transplants
Refractory materials
Non-Hodgkin's Lymphoma
Immunoconjugates
Chemotherapy
Clinical Trials
Clinical Pharmacology
Monoclonal Antibodies
Cells
B-Cell Lymphoma
Patient Safety
Combination Drug Therapy
Lymphoma
Guidelines
Safety
Therapeutics

Keywords

  • Follicular lymphoma
  • I-131 tositumomab
  • Lymphoma
  • Monoclonal antibody
  • Radioimmunoconjugates
  • Radioimmunotherapy
  • Transplant

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

I-131 tositumomab. / William, Basem M.; Bierman, Philip Jay.

In: Expert Opinion on Biological Therapy, Vol. 10, No. 8, 08.2010, p. 1271-1278.

Research output: Contribution to journalReview article

William, Basem M. ; Bierman, Philip Jay. / I-131 tositumomab. In: Expert Opinion on Biological Therapy. 2010 ; Vol. 10, No. 8. pp. 1271-1278.
@article{41949ca2943e4622b6e53fcad1a58e8b,
title = "I-131 tositumomab",
abstract = "Importance of the field: Follicular lymphoma (FL) is a subgroup of B-cell Non-Hodgkin's lymphomas (NHL) that account for 15 30{\%} of all lymphomas. I-131 tositumomab is a radiommunoconjugate of 131I and the anti-CD20 monoclonal antibody tositumomab. It is one of two available radioimmunoconjugates for the treatment of recurrent, refractory, or transformed FL. Areas covered in this review: This review describes the clinical pharmacology of I-131 tositumomab, dosing and administration guidelines, and the key clinical trials providing evidence of its efficacy and safety in patients with FL, transformed, or other aggressive B-NHL, in combination with chemotherapy, or its incorporation in transplant conditioning regimens. This review also covers safety and regulatory concerns regarding the use of I-131 tositumomab. What the reader will gain: This review critically appraises the clinical trials behind approval of I-131 tositumomab as a second-line agent for FL and also outlines the data supporting its use in the upfront setting. Take home message: I-131 tositumomab is a safe and effective option for patients with recurrent, refractory, or transformed FL and carries promise in the upfront treatment of FL, aggressive B-NHL, and as a transplant conditioning regimen.",
keywords = "Follicular lymphoma, I-131 tositumomab, Lymphoma, Monoclonal antibody, Radioimmunoconjugates, Radioimmunotherapy, Transplant",
author = "William, {Basem M.} and Bierman, {Philip Jay}",
year = "2010",
month = "8",
doi = "10.1517/14712598.2010.504707",
language = "English (US)",
volume = "10",
pages = "1271--1278",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - I-131 tositumomab

AU - William, Basem M.

AU - Bierman, Philip Jay

PY - 2010/8

Y1 - 2010/8

N2 - Importance of the field: Follicular lymphoma (FL) is a subgroup of B-cell Non-Hodgkin's lymphomas (NHL) that account for 15 30% of all lymphomas. I-131 tositumomab is a radiommunoconjugate of 131I and the anti-CD20 monoclonal antibody tositumomab. It is one of two available radioimmunoconjugates for the treatment of recurrent, refractory, or transformed FL. Areas covered in this review: This review describes the clinical pharmacology of I-131 tositumomab, dosing and administration guidelines, and the key clinical trials providing evidence of its efficacy and safety in patients with FL, transformed, or other aggressive B-NHL, in combination with chemotherapy, or its incorporation in transplant conditioning regimens. This review also covers safety and regulatory concerns regarding the use of I-131 tositumomab. What the reader will gain: This review critically appraises the clinical trials behind approval of I-131 tositumomab as a second-line agent for FL and also outlines the data supporting its use in the upfront setting. Take home message: I-131 tositumomab is a safe and effective option for patients with recurrent, refractory, or transformed FL and carries promise in the upfront treatment of FL, aggressive B-NHL, and as a transplant conditioning regimen.

AB - Importance of the field: Follicular lymphoma (FL) is a subgroup of B-cell Non-Hodgkin's lymphomas (NHL) that account for 15 30% of all lymphomas. I-131 tositumomab is a radiommunoconjugate of 131I and the anti-CD20 monoclonal antibody tositumomab. It is one of two available radioimmunoconjugates for the treatment of recurrent, refractory, or transformed FL. Areas covered in this review: This review describes the clinical pharmacology of I-131 tositumomab, dosing and administration guidelines, and the key clinical trials providing evidence of its efficacy and safety in patients with FL, transformed, or other aggressive B-NHL, in combination with chemotherapy, or its incorporation in transplant conditioning regimens. This review also covers safety and regulatory concerns regarding the use of I-131 tositumomab. What the reader will gain: This review critically appraises the clinical trials behind approval of I-131 tositumomab as a second-line agent for FL and also outlines the data supporting its use in the upfront setting. Take home message: I-131 tositumomab is a safe and effective option for patients with recurrent, refractory, or transformed FL and carries promise in the upfront treatment of FL, aggressive B-NHL, and as a transplant conditioning regimen.

KW - Follicular lymphoma

KW - I-131 tositumomab

KW - Lymphoma

KW - Monoclonal antibody

KW - Radioimmunoconjugates

KW - Radioimmunotherapy

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=77954687202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954687202&partnerID=8YFLogxK

U2 - 10.1517/14712598.2010.504707

DO - 10.1517/14712598.2010.504707

M3 - Review article

C2 - 20590521

AN - SCOPUS:77954687202

VL - 10

SP - 1271

EP - 1278

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 8

ER -